Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01)

Journal of Clinical Oncology

Volumn 32, Issue 20, 2014, Pages 2159-2165

  De Azambuja, Evandro ^a,b   Procter, Marion J ^d   Van Veldhuisen, Dirk J ^h   Agbor Tarh, Dominique ^d   Metzger Filho, Otto ⁱ   Steinseifer, Jutta ^j   Untch, Michael ^l   Smith, Ian E ^f   Gianni, Luca ⁿ   Baselga, Jose ^o   Jackisch, Christian ^m   Cameron, David A ^e   Bell, Richard ^p   Leyland Jones, Brian ^q   Dowsett, Mitch ^g   Gelber, Richard D ⁱ   Piccart Gebhart, Martine J ^a,c   Suter, Thomas M ^k  

^a JULES BORDET INSTITUTE   (Belgium)

^b Breast European Adjuvant Study Team ^*  (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k BERN UNIVERSITY HOSPITAL   (Switzerland)

^l HELIOS Klinikum Berlin   (Germany)

^m Klinikum Offenbach   (Germany)

ⁿ San Raf faele Institute   (Italy)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p GEELONG HOSPITAL   (Australia)

^q Edith Sanford Breast Cancer Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY CANCER; FEMALE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; LOGISTIC MODELS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; VENTRICULAR FUNCTION, LEFT;

EID: 84905858933     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.9288     Document Type: Article

References (20)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
3. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
4. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
5. Procter M, Suter TM, de Azambuja E, et al: Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422-3428, 2010
6. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
7. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244, 2011
8. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet 382:1021-1028, 2013
9. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007 (Pubitemid 47477261)
10. Serrano C, Cortés J, De Mattos-Arruda L, et al: Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors. Ann Oncol 23:897-902, 2012
11. Chen J, Long JB, Hurria A, et al: Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504-2512, 2012
12. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005 (Pubitemid 46211501)
13. Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826, 2005 (Pubitemid 46657379)
14. Lee KF, Simon H, Chen H, et al: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398, 1995
15. Erickson SL, O'Shea KS, Ghaboosi N, et al: ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2- and heregulin-deficient mice. Development 124:4999-5011, 1997 (Pubitemid 28025125)
16. De Keulenaer GW, Doggen K, Lemmens K: The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106:35-46, 2010
17. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
18. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
19. Ewer MS, Ewer SM: Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cardiol 7:564-575, 2010
20. Curigliano G, Cardinale D, Suter T, et al: Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23:vii155-vii166, 2012